One Biosciences secures €15 million in Series A financing to advance its AI-driven single-cell oncology platform, OneMap™, aimed at enhancing cancer treatment and clinical trial optimization.

Information on the Target

One Biosciences is a precision oncology technology company specializing in clinical-grade single-cell tumor transcriptomic profiling. Established in 2020 by Dr. Céline Vallot from the Curie Institute and Home Biosciences, the company aims to enhance treatment decision-making by decoding tumor heterogeneity from standard clinical samples. Its proprietary platform, OneMap™, leverages artificial intelligence to create detailed functional profiles of patient tumors, with the goal of optimizing therapy development and clinical trial outcomes.

This recent funding round of €15 million in Series A financing marks a significant milestone for One Biosciences, bringing its total funding to over €20 million. This capital will not only support the clinical development of OneMap™ but also facilitate the scaling of strategic partnerships with leading pharmaceutical and biotechnology firms, reinforcing the company's mission of improving patient care through innovative technology.

Industry Overview in France

The biotechnology industry in France has been a dynamic and rapidly developing sector, characterized by strong government support and a wealth of talent emerging from academic institutions. France has positioned itself as a leader in lif